Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

Pediatric Infectious Disease Journal

Volumn 21, Issue 7, 2002, Pages 653-659

  Church, Joseph A ^a,k   Cunningham, Coleen ^b   Hughes, Michael ^c   Palumbo, Paul ^d   Mofenson, Lynne M ^e   Delora, Patrizia ^g   Smith, Elizabeth ^h   Wiznia, Andrew ⁱ   Purdue, Lynette ^h   Hawkins, Elizabeth ^f   Sista, Prakash ^j  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e Eunice Kennedy Shriver National Institute of Child Health and Human Health   (United States)

^f AIDS Clinical Trials Group Operations Center   (United States)

^g HOFFMANN LA ROCHE INC   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ JACOBI MEDICAL CENTER   (United States)

^j Trimeris Inc   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

more..

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Human immunodeficiency virus entry inhibitor; Human immunodeficiency virus fusion inhibitor; T 20

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION PAIN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FOLLOW UP; HOSPITALIZATION; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MORTALITY; PRESCHOOL CHILD; PROBABILITY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMAN; INJECTIONS, SUBCUTANEOUS; LONG-TERM CARE; MALE; MAXIMUM TOLERATED DOSE; PROBABILITY; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL LOAD; HUMANS;

EID: 0036020193     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200207000-00010     Document Type: Article

References (20)

1. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease
2. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis
3. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
4. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analogue resistance
5. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
6. Antiretroviral therapy for previously treated patients
7. Current evidence and future direction for targeting HIV entry-therapeutic and prophylactic strategies
8. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
9. Atomic structure of the ectodomain from HIV-1 gp41
10. Core structure of gp41 from the HIV envelope glycoprotein
11. Structural rearrangements in the transmembrane glycoprotein after receptor binding
12. Capture of an early fusion-active conformation of HIV-1 gp41
13. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp 41 are potent inhibitors of virus infection
14. Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-1-infected individual
15. Safety, pharmacokinetics and antiviral activity of T-20 as a single agent in heavily pre-treated patients [Abstract LB13]
16. Guidelines for flow cytometric immunophenotyping: A report from the National Institute of Allergy and Infectious Diseases, Division of AIDS
17. Effects of peptideinduced humoral responses and preexisting antibodies in nonhuman primates and HIV-infected patients following chronic administration of T-20
18. Pharmacokinetics of selected doses of T-20, a fusion inhibitor, in HIV-1-infected children
19. Forty-eight week analysis of patients receiving T-20 as a component of multidrug salvage therapy
20. Safety and antiviral activity of chronic subcutaneous administration of T-20 in HIV-1-infected children